放疗联合热疗治疗复发性卵巢癌患者的临床疗效及对患者免疫功能的影响

目的:探讨放疗联合热疗治疗复发性卵巢癌患者的临床疗效及对患者免疫功能的影响。方法:回顾性选取2011年1月-2014年5月在我院诊治的复发性卵巢癌患者99例,按治疗方法将患者分为对照组47例和观察组52例。对照组患者给予三维适行放射治疗,观察组在对照组的基础上给予盆腔部位热疗。治疗后,比较两组患者的临床疗效及免疫功能。结果:治疗后,对照组总缓解率为53.19%,观察组总缓解率为78.85%,显著高于对照组(P0.05);治疗后,观察组与对照组外周血中CD3+、CD4+及CD4+/CD8+含量均较治疗前明显升高(P0.05),而CD8+含量则显著降低(P0.05),且观察组患者CD3+、CD4+及CD4+/CD8+显著高于对照组(P0.05),CD8+水平则明显低于对照组(P0.05)。两组患者治疗后骨髓抑制、胃肠道反应及泌尿系统反应的发生率、1年及2年生存率比较均无显著性差异(P0.05),观察组治疗后3年生存率显著高于对照组(P0.05)。结论:与单纯三维适行放射治疗相比,放疗联合热疗能有效提高复发性卵巢癌的临床疗效,显著增强患者免疫功能,延长生存期,且不会增加不良反应。

Clinical Efficacy of Radiotherapy Combined with Hyperthermia in the Treatment of Patients with Recurrent Ovarian Cancer and its Effect on the Immune Function

ABSTRACT Objective: To investigate the clinical efficacy of radiotherapy combined with hyperthermia in the treatment of patients with recurrent ovarian cancer and the effect on the immune function. Methods: A total of 99 cases of patients with recurrent ovarian cancer who were diagnosed and treated in our hospital from January 2011 to May 2014 were retrospectively selected. The patients were divided into the control group (n=47) and the observation group (n=52) according to the treatment method. Patients in the control group were given three-dimensional adaptive radiotherapy. The observation group was given pelvic hyperthermia on the basis of control group. After treatment, the clinical efficacy and immune function were compared after treatment between two groups of patients. Results: After treatment, the total remission rate was 53.19% in the control group and 78.85% in the observation group, which was significantly higher in the control group (P<0.05). After treatment, the levels of CD3⁺, CD4⁺ and CD4⁺/CD8⁺ in the peripheral blood of both groups were both significantly higher than those before treatment(P<0.05), while the levels of CD8⁺ were significantly decreased (P<0.05). The CD3⁺, CD4⁺ and CD4⁺/CD8⁺ levels in the observation group were significantly higher than those in the control group (P<0.05), while the level of CD8⁺ was significantly lower than that of the control group(P<0.05). There was no significant difference in the incidence of myelosuppression, gastrointestinal and urinary system reactions, and 1-year and 2-year survival rates between the observation group and the control group after treatment (P>0.05). The 3-year survival rate was significantly higher than in the observation group than that of the control group (P<0.05). Conclusion: Compared with simple three-dimensional radiotherapy, radiotherapy combined with hyperthermia can effectively improve the clinical efficacy of recurrent ovarian cancer, it could promote the remission, significantly enhance the immune function, prolong the survival without no increase of adverse reactions.